Previous 10 | Next 10 |
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors PR Newswire SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...
ALX Oncology is developing a novel CD47 inhibitor and has differentiated itself from its competitors with its approach. Recent data updates have reaffirmed my original thoughts of their likelihood of success in several indications. I was previously neutral on ALX Oncology, given t...
Zai will have greater China rights to two Blueprint next-gen EGFR candidates aimed at non-small cell lung cancer (NSCLC), which Blueprint says have first-in-class potential. Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment ...
I-Mab (NASDAQ:IMAB) has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical. I-Mab shares up more than 8% premarket. The agreement allows for the development, manufacturing and commercialization of I-Mab's highly differentiated long-acting recombinant h...
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa PR Newswire The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medic...
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC PR Newswire Preclinical d ata of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity Both studies ar...
HONG KONG, Nov. 08, 2021 (GLOBE NEWSWIRE) -- DayDayCook (“DDC”), a leading content driven direct-to-consumer brand in China , today announces the addition of three new independent directors to its Board of Directors: Conor Chia-Hung Yang, Matthew Gene Mouw, and Sam Shih. D...
I-Mab (NASDAQ:IMAB) and Roche Diagnostics (OTCQX:RHHBY) and have announced a strategic collaboration to co-develop companion diagnostics solutions for I-Mab's innovative pipeline. Under the collaboration, the companies will jointly develop companion diagnostics solutions to accelerate th...
I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE PR Newswire SHANGHAI and GAITHERSBURG, Md. , Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq:...
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- DDC Enterprise Limited (the “Company” or “DDC”), a digital publisher and merchandising company that owns and operates the brand DayDayCook, and Ace Global Business Acquisition Limited (“Ace”) (NASDAQ: ACBA...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...